Patents by Inventor Gabi Tarcic

Gabi Tarcic has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods and systems for determining oncogenic index of patient specific mutations
    Patent number: 11015229
    Abstract: Methods for determining various oncogenic-related indexes of patient specific mutations are provided. The methods provided allow determination and grading of various patient specific mutations and qualitative and quantitative determination of various related oncogenic indexes.
    Type: Grant
    Filed: July 20, 2015
    Date of Patent: May 25, 2021
    Assignee: NOVELLUSDX LTD.
    Inventors: Gabi Tarcic, Yoram Altschuler, Michael Vidne
  • METHODS FOR IN VITRO SITE-DIRECTED MUTAGENESIS USING GENE EDITING TECHNOLOGIES
    Publication number: 20200370035
    Abstract: The invention relates to methods for performing in vitro site-directed mutagenesis of a targeted gene or genes. In another aspect, the invention includes in vitro site-directed mutagenesis kits comprising a ribonucleotide particle (RNP), an oligonucleotide, a buffer, a cell-free extract, and instructional material for use thereof.
    Type: Application
    Filed: June 11, 2020
    Publication date: November 26, 2020
    Applicants: Christiana Care Health Services, Inc., Novellusdx Ltd.
    Inventors: Eric B. Kmiec, Michael Vidne, Gabi Tarcic
  • Methods and systems for identifying patient specific driver mutations
    Patent number: 10815477
    Abstract: Methods for identifying patient specific driver mutations are provided. The methods provided identify specific patient derived markers associated with aberrant signal transduction pathways, in biological samples of a cancer patient.
    Type: Grant
    Filed: July 11, 2018
    Date of Patent: October 27, 2020
    Assignee: NOVELLUSDX LTD.
    Inventors: Yoram Altschuler, Gabi Tarcic
  • Methods for determining drug response of patient specific mutations
    Patent number: 10550439
    Abstract: Methods for identifying and determining drug response of patient specific oncogenic mutations are provided. The methods provided identify specific (personalized) drug treatment based on the effect of drug on the patient derived markers associated with aberrant signal transduction pathways, in biological samples of a cancer patient.
    Type: Grant
    Filed: July 20, 2015
    Date of Patent: February 4, 2020
    Assignee: NovellusDX Ltd.
    Inventors: Gabi Tarcic, Yoram Altschuler
  • METHODS FOR IN VITRO SITE-DIRECTED MUTAGENESIS USING GENE EDITING TECHNOLOGIES
    Publication number: 20190359973
    Abstract: The invention relates to methods for performing in vitro site-directed mutagenesis of a targeted gene or genes. In another aspect, the invention includes in vitro site-directed mutagenesis kits comprising a ribonucleotide particle (RNP), an oligonucleotide, a buffer, a cell-free extract, and instructional material for use thereof.
    Type: Application
    Filed: January 9, 2018
    Publication date: November 28, 2019
    Applicants: Christiana Care Health Services, Inc., Novellusdx Ltd.
    Inventors: Eric B. Kmiec, Michael Vidne, Gabi Tarcic
  • METHODS AND SYSTEMS FOR IDENTIFYING PATIENT SPECIFIC DRIVER MUTATIONS
    Publication number: 20180320167
    Abstract: Methods for identifying patient specific driver mutations are provided. The methods provided identify specific patient derived markers associated with aberrant signal transduction pathways, in biological samples of a cancer patient.
    Type: Application
    Filed: July 11, 2018
    Publication date: November 8, 2018
    Inventors: Yoram ALTSCHULER, Gabi TARCIC
  • Methods and systems for identifying patient specific driver mutations
    Patent number: 10047356
    Abstract: Methods for identifying patient specific driver mutations are provided. The methods provided identify specific patient derived markers associated with aberrant signal transduction pathways, in biological samples of a cancer patient.
    Type: Grant
    Filed: January 16, 2014
    Date of Patent: August 14, 2018
    Assignee: NOVELLUSDX LTD.
    Inventors: Yoram Altschuler, Gabi Tarcic
  • METHODS AND SYSTEMS FOR DETERMINING ONCOGENIC INDEX OF PATIENT SPECIFIC MUTATIONS
    Publication number: 20170159138
    Abstract: Methods for determining various oncogenic-related indexes of patient specific mutations are provided. The methods provided allow determination and grading of various patient specific mutations and qualitative and quantitative determination of various related oncogenic indexes.
    Type: Application
    Filed: July 20, 2015
    Publication date: June 8, 2017
    Inventors: Gabi TARCIC, Yoram ALTSCHULER, Michael VIDNE
  • METHODS FOR DETERMINING DRUG RESPONSE OF PATIENT SPECIFIC MUTATIONS
    Publication number: 20170159137
    Abstract: Methods for identifying and determining drug response of patient specific oncogenic mutations are provided. The methods provided identify specific (personalized) drug treatment based on the effect of drug on the patient derived markers associated with aberrant signal transduction pathways, in biological samples of a cancer patient.
    Type: Application
    Filed: July 20, 2015
    Publication date: June 8, 2017
    Inventors: Gabi TARCIC, Yoram ALTSCHULER
  • METHODS AND SYSTEMS FOR IDENTIFYING PATIENT SPECIFIC DRIVER MUTATIONS
    Publication number: 20150353922
    Abstract: Methods for identifying patient specific driver mutations are provided. The methods provided identify specific patient derived markers associated with aberrant signal transduction pathways, in biological samples of a cancer patient.
    Type: Application
    Filed: January 16, 2014
    Publication date: December 10, 2015
    Applicant: NOVELLUSDX LTD.
    Inventors: Yoram Altschuler, Gabi Tarcic